KSPWFTTL TFA
产品介绍 | KSPWFTTL TFA 是一种来自 p15E 跨膜蛋白的免疫显性 Kb 限制性表位。KSPWFTTL TFA 可以恢复肿瘤系对抗 AKR/Gross MuLV 细胞毒性 T 淋巴细胞的敏感性。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | KSPWFTTL TFA is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL TFA can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes. | ||||||||||||||||
体外研究 |
KSPWFTTL TFA is derived from the retroviral p15 TM envelope protein. The cytolytic T-lymphocyte (CTL)-insusceptible, variant cl.18-5 clonal line, after pulsed with the KSPWFTTL TFA peptide, becomes susceptible to lysis by antiviral CTL. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 | |||||||||||||||||
体内研究 | |||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
H2O : 66.67 mg/mL (60.99 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*以上所有助溶剂都可在 西域 网站选购。
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
参考文献 |
|